Transcept Pharmaceuticals to Host Conference Call to Discuss Broadened Intermezzo® Commercialization Strategy and New Consumer Advertising Campaign by Purdue Pharma
Call Scheduled for Tuesday, November 27, 2012 at 8:30 a.m. ET
POINT RICHMOND, Calif., Nov. 26, 2012 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, announced that it will host a conference call to discuss the broadened Intermezzo® commercialization strategy and consumer advertising campaign by Purdue Pharmaceutical Products, L.P.
Conference Call Information
Date: Tuesday, November 27, 2012
Time: 8:30 a.m. ET
Dial-in (U.S.): 877-638-4558
Dial-in (International): 914-495-8537
A simultaneous web cast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of the call will be available on the website shortly after the conclusion of the call until January 30, 2013.
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. Transcept is currently conducting a Phase 2 study of an investigational product, TO-2061, in patients with obsessive-compulsive disorder. For further information about Transcept, please visit www.transcept.com. For information about Intermezzo, please visit www.IntermezzoRx.com.
Transcept Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
SOURCE Transcept Pharmaceuticals, Inc.
More by this Source
Transcept Pharmaceuticals Reports Fourth Quarter And Full Year 2013 Financial Results
Mar 13, 2014, 16:05 ET
Transcept Pharmaceuticals Statement on Dismissal of Derivative Lawsuit
Jan 13, 2014, 18:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.